As part of a larger research program to develop probes for nuclear imaging to study the activity of central oncogenes,5 we and others have shown in preclinical models and clinical biopsies that the transferrin receptor (TFRC) is upregulated in tumors with important oncogenic drivers like the transcription factor MYC and the cytosolic Ser/Thr kinase mammalian target of rapamycin (mTOR).6, -8 Hepatocellular carcinoma frequently harbors MYC and mTOR hyperactivity. This evidence concerns the gene TFRC and hepatocellular carcinoma.